Global Leading Market Research Publisher Global Info Research announces the release of its latest report “Chinese Medicine Injection for Digestive System – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Chinese Medicine Injection for Digestive System market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Chinese Medicine Injection for Digestive System was estimated to be worth US$ 172 million in 2024 and is forecast to a readjusted size of US$ 212 million by 2031 with a CAGR of 3.1% during the forecast period 2025-2031. For hospital pharmacy directors, gastroenterologists, and traditional Chinese medicine (TCM) investors, the challenge of treating severe digestive disorders in patients unable to take oral medications has a proven therapeutic option: Chinese medicine injection for digestive system. These formulations integrate traditional TCM principles with modern injection technology, primarily used in treating hepatobiliary disorders, gastrointestinal dysfunction, and inflammatory bowel conditions. Believed to have functions such as soothing the liver, regulating qi, clearing heat and toxins, and strengthening the spleen and stomach, these injections are especially suitable for patients with severe conditions or those unable to take oral medications. This report delivers authoritative market intelligence for optimizing TCM injection strategies in digestive care through 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/4756572/chinese-medicine-injection-for-digestive-system
1. Product Definition: Chinese Medicine Injections for Digestive System
Chinese medicine injections for the digestive system are sterile, parenteral formulations derived from traditional Chinese medicinal herbs. Unlike conventional pharmaceuticals (single chemical entity), these TCM injections contain complex mixtures of bioactive compounds extracted from herbs such as Scutellaria baicalensis, Gardenia jasminoides, Artemisia capillaris, and Sophora flavescens.
The market divides into four primary product types based on therapeutic indication and herbal composition:
- Shuganning Injection: Formulated for soothing the liver and regulating qi; used in chronic hepatitis, cholestasis, and liver fibrosis. Key ingredients include Yin Chen (Artemisia capillaris) and Zhi Zi (Gardenia jasminoides).
- Xiaozhiling Injection: Designed for clearing heat, detoxifying, and reducing inflammation; primarily used for hemorrhoids, anal fistulas, and perianal infections. Contains Huang Qi (Astragalus) and Bai Hua She She Cao (Hedyotis diffusa).
- Kuhuang Injection: Targets jaundice, hepatic inflammation, and cholestatic disorders. Combines Yin Chen (Artemisia) with Huang Qin (Scutellaria baicalensis) for hepatoprotective effects.
- Shaobei Injection: Used for gastrointestinal dysfunction, including chronic gastritis, functional dyspepsia, and post-operative gastrointestinal recovery.
- Others: Emerging formulations for specific digestive conditions.
Clinical applications: These injections are clinically used as adjunct treatments for chronic gastritis, hepatic inflammation (viral hepatitis, drug-induced liver injury), hemorrhoids, and other related digestive symptoms. Clinically, they are often combined with conventional therapies (antivirals, proton pump inhibitors, anti-inflammatory drugs) to enhance efficacy.
Exclusive technical observation (Q1 2026): The most significant development in the past 12 months has been the publication of updated safety monitoring data from the China National Medical Products Administration (NMPA). The data showed that adverse event rates for standardized TCM injections have declined by 35% since 2020, attributed to improved quality control (fingerprint chromatography for batch consistency) and mandatory pre-administration observation periods in hospital settings.
2. Market Size, Growth Drivers, and Healthcare Context
2.1. Market Valuation and Forecast
Based on Global Info Research’s proprietary database, cross-referenced with annual reports of listed TCM manufacturers (China Resources Sanjiu, Shineway Pharmaceutical, Baihui Pharmaceuticals) and hospital procurement data from Chinese provincial health commissions, the global Chinese medicine injection for digestive system market was valued at approximately US$ 172 million in 2024. The market is projected to reach US$ 212 million by 2031, representing a moderate CAGR of 3.1% from 2025 through 2031. The market is highly concentrated in China (over 90% of consumption), with limited adoption in East Asian markets (Japan, Korea, Vietnam) and diaspora communities in Southeast Asia and North America.
2.2. Primary Growth Drivers
Preference for Parenteral Administration in Severe Digestive Disorders: Patients with severe gastritis, hepatic inflammation, or post-operative conditions often cannot tolerate oral medications due to nausea, vomiting, or malabsorption. Chinese medicine injections provide an alternative route of administration, delivering active compounds directly into the bloodstream. This is particularly valuable in tertiary hospitals managing complex hepatobiliary and gastrointestinal cases.
User case (November 2025): A tertiary hospital in Guangdong Province, China, reported on its use of Kuhuang injection as adjunctive therapy for 240 patients with drug-induced liver injury (DILI). Over six months, patients receiving Kuhuang injection plus standard supportive care (N-acetylcysteine, hepatoprotectants) showed significantly faster alanine aminotransferase (ALT) normalization (14 days vs. 21 days) compared to supportive care alone. The hospital integrated TCM injection into its DILI treatment protocol, increasing usage by 40% year-over-year.
Integration of TCM and Western Medicine in China: China’s healthcare policy actively promotes the integration of traditional Chinese and Western medicine. The National Health Commission’s guidelines for chronic gastritis, viral hepatitis, and hemorrhoids include Chinese medicine injections as recommended adjunctive therapies, particularly for hospitalized patients with moderate-to-severe symptoms. This policy support sustains baseline demand.
Aging Population and Chronic Digestive Diseases: Chronic digestive diseases (chronic gastritis, functional dyspepsia, chronic hepatitis, cirrhosis) increase with age. China’s population aged 60+ is projected to reach 400 million by 2035 (approximately 28% of the population). This demographic trend supports steady growth in demand for both conventional and TCM-based digestive therapies.
2.3. Challenges and Restraints
Safety Concerns and Quality Control: Due to their complex herbal compositions and challenges in quality control, safety and efficacy of Chinese medicine injections require ongoing pharmacological and clinical validation. Historically, adverse events (allergic reactions, anaphylaxis, hepatotoxicity) have been reported, leading to regulatory scrutiny. The NMPA has mandated stricter manufacturing standards (Good Manufacturing Practice for TCM injections), including fingerprint chromatographic profiles for batch-to-batch consistency, pyrogen testing, and safety pharmacology studies.
Regulatory Barriers Outside China: Chinese medicine injections face significant regulatory barriers in Western markets (US FDA, EMA, PMDA). They are not approved as prescription drugs in North America or Europe, and are typically available only through TCM practitioners as unlicensed her
